Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.

NCT00091507 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to test the impact of pharmacological myocardial metabolic support, in the form of intravenous (IV) glucose, insulin and potassium (GIK), for the treatment of patients with threatened or established acute myocardial infarction (AMI).

Interventions

  • DRUG Placebo
  • DRUG GIK

Study Locations (13)

Massachusetts

  • Brockton Site — Brockton
  • Concord Site — Concord

Texas

  • Dallas Site — Dallas
  • El Paso Site — El Paso

Alaska

  • Anchorage Site — Anchorage

Connecticut

  • New Haven Site — New Haven

Georgia

  • Macon Site — Macon

Minnesota

  • St. Paul Site — Saint Paul

New Mexico

  • Albuquerque Site — Albuquerque

Pennsylvania

  • Hershey Site — Hershey

Trial Details

FieldValue
Enrollment Target 911 participants
Start Date 2006-11
Est. Completion 2012-08
Phase Phase 3

Sponsor

Tufts Medical Center

132 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00091507

The ClinicalTrials.gov registry entry for NCT00091507 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 911 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 132 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 6 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00091507 reports 13 study locations spanning 11 distinct geographic areas — top geographies include Massachusetts, Texas, Alaska. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00091507 about?

NCT00091507 is a clinical study titled "IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.". The purpose of this study is to test the impact of pharmacological myocardial metabolic support, in the form of intravenous (IV) glucose, insulin and potassium (GIK), for the treatment of patients with threatened or established acute myocardial infarction (AMI).

What is the current status of trial NCT00091507?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 911 participants. The study started on 2006-11. Estimated completion is 2012-08.

What conditions does trial NCT00091507 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Coronary Disease, Heart Failure, Congestive. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00091507?

The interventions under investigation include: Placebo (DRUG), GIK (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00091507?

This trial is sponsored by Tufts Medical Center, which has 132 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00091507 being conducted?

This trial has 13 study locations across Alaska, Connecticut, Georgia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial